Yongmin Liu, M.D., Ph.D.
Staff Scientist

Center for Cancer Research
National Cancer Institute

Building 37, Room 4032
Bethesda, MD 20892-4254
301-435-7844

Dr. Liu's current studies focus on mitochondrial toxicity induced by anti-retroviral drugs and, in particular, nucleoside reverse transcriptase inhibitors (NRTIs). His projects include: 1) structural and functional mitochondrial changes in patas monkey fetuses exposed to human-equivalent antiretroviral protocols during gestation; 2) metabolic and bioenegetic consequences NRTIs exposures in cardiomyocytes and monkey tissues; and 3) the use of chemopreventive agents in reversal of NRTI-induced mitochondrial toxicity.

Areas of Expertise
NRTI

Dr. Liu's current studies focus on mitochondrial toxicity induced by anti-retroviral drugs and, in particular, nucleoside reverse transcriptase inhibitors (NRTIs). His projects include: 1) structural and functional mitochondrial changes in patas monkey fetuses exposed to human-equivalent antiretroviral protocols during gestation; 2) metabolic and bioenegetic consequences NRTIs exposures in cardiomyocytes and monkey tissues; and 3) the use of chemopreventive agents in reversal of NRTI-induced mitochondrial toxicity.

Selected Publications
  1. Liu Y, Shim E, Nguyen P, Gibbons AT, Mitchell JB, Poirier MC.
    Toxicol. Sci.. 2014. [ Journal Article ]
  2. Olivero OA, Torres LR, Gorjifard S, Momot D, Marrogi E, Divi RL, Liu Y, Woodward RA, Sowers MJ, Poirier MC.
    J. Infect. Dis.. 208: 244-8, 2013. [ Journal Article ]
  3. Herman EH, Knapton A, Liu Y, Lipshultz SE, Estis J, Todd J, Woodward RA, Cochran T, Zhang J, Poirier MC.
    Toxicol Pathol. 2013. [ Journal Article ]
  4. Liu Y, Nguyen P, Baris TZ, Poirier MC.
    Cardiovasc. Toxicol.. 12: 123-34, 2012. [ Journal Article ]
  5. Liu Y, Borchert GL, Donald SP, Diwan BA, Anver M, Phang JM.
    Cancer Res. 69: 6414-22, 2009. [ Journal Article ]

Dr. Liu graduated from Qingdao University School of Medicine with a medical degree in 1987. In 1996, he received his Ph.D. degree in oncology from Peking Union Medical School (PUMC) and the Chinese Academy of Medical Science (CAMS) in Beijing, China. Dr. Liu had two postdoctoral internships, one at the University of Texas Health Science at San Antonio and one at the Baylor College of Medicine, which focused on the mechanistic studies of HPV in human cancers and the AP-1 transcription factor as a cancer prevention target in breast cancer, respectively. Subsequently, between 2001 and 2007, Dr. Liu worked as a research fellow in the Laboratory of Comparative Carcinogenesis, CCR. His work during this period of time focused on cancer prevention, particularly metabolic intervention of cancer. From 2007 to 2009, Dr. Liu served as a research scientist with SAIC-Frederick, Inc. He is currently a staff scientist with Dr. Miriam Poirier in the Carcinogen-DNA Interactions Section in the Laboratory of Cancer Biology and Genetics.

Summary

Dr. Liu's current studies focus on mitochondrial toxicity induced by anti-retroviral drugs and, in particular, nucleoside reverse transcriptase inhibitors (NRTIs). His projects include: 1) structural and functional mitochondrial changes in patas monkey fetuses exposed to human-equivalent antiretroviral protocols during gestation; 2) metabolic and bioenegetic consequences NRTIs exposures in cardiomyocytes and monkey tissues; and 3) the use of chemopreventive agents in reversal of NRTI-induced mitochondrial toxicity.

Areas of Expertise
NRTI

Research

Dr. Liu's current studies focus on mitochondrial toxicity induced by anti-retroviral drugs and, in particular, nucleoside reverse transcriptase inhibitors (NRTIs). His projects include: 1) structural and functional mitochondrial changes in patas monkey fetuses exposed to human-equivalent antiretroviral protocols during gestation; 2) metabolic and bioenegetic consequences NRTIs exposures in cardiomyocytes and monkey tissues; and 3) the use of chemopreventive agents in reversal of NRTI-induced mitochondrial toxicity.

Publications

Selected Publications
  1. Liu Y, Shim E, Nguyen P, Gibbons AT, Mitchell JB, Poirier MC.
    Toxicol. Sci.. 2014. [ Journal Article ]
  2. Olivero OA, Torres LR, Gorjifard S, Momot D, Marrogi E, Divi RL, Liu Y, Woodward RA, Sowers MJ, Poirier MC.
    J. Infect. Dis.. 208: 244-8, 2013. [ Journal Article ]
  3. Herman EH, Knapton A, Liu Y, Lipshultz SE, Estis J, Todd J, Woodward RA, Cochran T, Zhang J, Poirier MC.
    Toxicol Pathol. 2013. [ Journal Article ]
  4. Liu Y, Nguyen P, Baris TZ, Poirier MC.
    Cardiovasc. Toxicol.. 12: 123-34, 2012. [ Journal Article ]
  5. Liu Y, Borchert GL, Donald SP, Diwan BA, Anver M, Phang JM.
    Cancer Res. 69: 6414-22, 2009. [ Journal Article ]

Biography

Dr. Liu graduated from Qingdao University School of Medicine with a medical degree in 1987. In 1996, he received his Ph.D. degree in oncology from Peking Union Medical School (PUMC) and the Chinese Academy of Medical Science (CAMS) in Beijing, China. Dr. Liu had two postdoctoral internships, one at the University of Texas Health Science at San Antonio and one at the Baylor College of Medicine, which focused on the mechanistic studies of HPV in human cancers and the AP-1 transcription factor as a cancer prevention target in breast cancer, respectively. Subsequently, between 2001 and 2007, Dr. Liu worked as a research fellow in the Laboratory of Comparative Carcinogenesis, CCR. His work during this period of time focused on cancer prevention, particularly metabolic intervention of cancer. From 2007 to 2009, Dr. Liu served as a research scientist with SAIC-Frederick, Inc. He is currently a staff scientist with Dr. Miriam Poirier in the Carcinogen-DNA Interactions Section in the Laboratory of Cancer Biology and Genetics.